AGI discontinues lead candidate Rezular for IBS
This article was originally published in Scrip
Executive Summary
AGI Therapeutics has discontinued its lead product, Rezular (arverapamil), following its failure to meet the primary endpoint of its Phase III study for diarrhoea-predominant irritable bowel syndrome (IBS-D).